What is Leash Bio?
Leash Bio operates at the intersection of biotechnology and artificial intelligence, addressing a fundamental bottleneck in drug discovery: the lack of high-quality, structured experimental data. While machine learning has catalyzed breakthroughs in various fields, the company posits that medicinal chemistry requires a purpose-built dataset to achieve similar success. To this end, Leash Bio is developing a proprietary platform that combines automated in-house protein production with DNA-encoded chemical libraries. By generating physical measurements at scale, the company is not only building a robust data foundation but also training generalizable machine learning models capable of accelerating the discovery of novel medicines across diverse protein targets.
How much funding has Leash Bio raised?
Leash Bio has raised a total of $9.3M across 1 funding round:
Angel/Seed
$9.3M
Angel/Seed (2024): $9.3M with participation from MFV Partners, SpringTide Ventures, Metaplanet, Mitsui & Co Global Investment, and Top Harvest Capital
Key Investors in Leash Bio
MFV Partners
MFV Partners is an early-stage venture capital firm specializing in deep tech investments, supporting visionary entrepreneurs who are developing innovative solutions in AI, robotics, and healthcare.
SpringTide Ventures
SpringTide Ventures focuses on leading early-stage financings for innovative healthcare companies, fostering collaboration to enhance care delivery and elevate health outcomes globally.
Metaplanet
Metaplanet is an early-stage investment firm that prioritizes long-term backing for mission-driven founders working on disruptive technologies in AI and the life sciences.
What's next for Leash Bio?
With this major enterprise-level funding, Leash Bio is poised to transition from its foundational development phase into a period of accelerated operational scaling. The strategic allocation of capital will likely focus on expanding its automated laboratory infrastructure and enhancing the predictive capabilities of its ML models. By bridging the gap between physical experimentation and computational modeling, the company aims to establish a new standard for data-driven drug discovery. As the firm continues to refine its proprietary datasets, it is expected to attract further interest from pharmaceutical partners seeking to leverage high-fidelity data to reduce the time and cost associated with bringing new therapeutics to market.
See full Leash Bio company page
